Tesamorelin: The FDA-Approved GHRH Analog That Targets Visceral Fat

In the research-peptide world, growth-hormone secretagogues like CJC-1295, ipamorelin, and sermorelin are familiar names — but tesamorelin stands apart. It is the only growth-hormone-releasing hormone (GHRH) analog with an FDA approval, backed by multiple Phase 3 trials and a specific clinical indication: reduction of excess visceral adipose tissue in HIV-associated lipodystrophy. Beyond that primary indication, tesamorelin has been studied in NAFLD, cognitive aging, and cardiometabolic contexts, giving it the richest clinical dataset of any GHRH-class peptide.

How Tesamorelin Works

Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH), the hypothalamic peptide that signals the pituitary to release growth hormone. The native GHRH molecule has a short half-life because of rapid degradation by DPP-IV (the same enzyme that clears endogenous GLP-1). Tesamorelin's N-terminal trans-3-hexenoic acid modification blocks DPP-IV cleavage, extending the plasma half-life enough to produce a sustained physiologic signal from a once-daily subcutaneous injection.

The key feature: tesamorelin preserves the pulsatile secretion pattern of endogenous growth hormone. Exogenous recombinant human growth hormone (rhGH) delivers a non-physiologic, sustained GH level that disrupts normal diurnal patterns and can impair insulin sensitivity. Tesamorelin, by prompting the pituitary rather than replacing it, maintains the natural pulse architecture of GH release — and with it a more favourable metabolic profile.

The HIV Lipodystrophy Indication

HIV-associated lipodystrophy is a syndrome of altered fat distribution — characterised by excess visceral abdominal fat combined with subcutaneous fat loss — seen in some patients on long-term antiretroviral therapy. The syndrome produces cosmetic concern, cardiometabolic risk, and quality-of-life issues. Tesamorelin was developed specifically to reduce the visceral fat component.

Phase 3 trials showed:

• Visceral adipose tissue (VAT) reduction of ~15–18% at 26 weeks
• Triglyceride reductions and improvements in non-HDL cholesterol
• No clinically meaningful loss of subcutaneous fat — the effect was specifically on visceral depots
• IGF-1 elevations within the physiologic range for most patients
• Transient hyperglycemia in some patients, especially those with underlying insulin resistance

Beyond HIV: NAFLD and Liver Research

Visceral fat and hepatic fat are tightly linked. If tesamorelin reduces visceral fat, might it also reduce hepatic fat? A series of mechanistic trials in HIV patients with NAFLD tested this directly:

• Hepatic fat fraction reduced significantly on tesamorelin vs placebo
• Liver enzymes (ALT) improved in parallel
• NAFLD activity scores (histological) trended toward improvement in biopsied cohorts

These are HIV-cohort trials, not general MASH populations, but they establish mechanistic proof-of-concept. Larger MASH trials outside HIV have not yet been conducted at approval scale.

Cognitive Aging Research

GHRH has receptor expression in the brain, and the GH/IGF-1 axis is implicated in cognitive aging. Small trials have investigated tesamorelin in mild cognitive impairment and healthy aging:

• Improvements in executive function and verbal memory in small Phase 2 trials
• Changes in cerebrospinal fluid biomarkers consistent with CNS GHRH engagement
• No definitive clinical outcome trial — sample sizes have been modest

The cognitive-aging story is suggestive but not established. No cognition-indicated approval exists.

Safety and Tolerability

The tesamorelin safety profile from its approved indication is characterised:

• Injection site reactions — the most common adverse event (redness, itching, rash at site)
• Arthralgia (joint pain) and peripheral edema — related to GH axis activation
• Hyperglycemia risk — mild in most patients; elevated in those with pre-existing insulin resistance or type 2 diabetes
• IGF-1 elevation — monitored during therapy; dose adjustments if IGF-1 climbs above physiologic range
• Contraindications: active malignancy, pituitary disease, pregnancy

How Tesamorelin Compares to Other GHRH-Class Peptides

Three important distinctions:

• vs CJC-1295: CJC-1295 is a modified GRF(1-29) analog, sometimes with DAC conjugation for extended half-life. CJC-1295 is not FDA-approved; tesamorelin is. Tesamorelin has clinical trial data; CJC-1295 does not at approval scale.
• vs sermorelin: Sermorelin is GRF(1-29) — the shortest biologically active GHRH fragment. It was previously FDA-approved for pediatric GH deficiency but was discontinued. Tesamorelin is a longer, stabilised, modified analog with a durable adult indication.
• vs ipamorelin: Ipamorelin is a ghrelin mimetic (GHSR agonist), not a GHRH analog. The two mechanisms converge on GH release but through different receptors. See our ipamorelin research review for the mechanistic contrast.

Practical Considerations

Daily subcutaneous injection is a meaningful commitment. Patients considering tesamorelin for its approved HIV lipodystrophy indication typically:

• Have documented excess abdominal fat and HIV-associated lipodystrophy
• Are followed by HIV specialists familiar with the drug's monitoring requirements (IGF-1, glucose, imaging of visceral fat)
• Expect visible visceral-fat reduction over 6–12 months, often requiring continued therapy for maintenance

For non-approved uses, the drug is only available via research supply or compounded through limited channels, with the usual off-label considerations.

Frequently Asked Questions

Primary sources:

• FDA Label — Egrifta (tesamorelin) Prescribing Information
• NEJM — Tesamorelin in HIV-associated Abdominal Fat Accumulation
• Lancet HIV — Tesamorelin for the Reduction of Hepatic Fat

Research disclaimer: This article is an educational summary of published tesamorelin research. Tesamorelin is FDA-approved only for reduction of excess abdominal fat in HIV-associated lipodystrophy. Any other use is off-label and should be discussed with a licensed clinician.